Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;18(8):1022-1039.
doi: 10.1016/S1470-2045(17)30445-X. Epub 2017 Jul 4.

Burden and Centralised Treatment in Europe of Rare Tumours: Results of RARECAREnet-a Population-Based Study

Collaborators, Affiliations

Burden and Centralised Treatment in Europe of Rare Tumours: Results of RARECAREnet-a Population-Based Study

Gemma Gatta et al. Lancet Oncol. .

Erratum in

Abstract

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.

Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000-07 and the corresponding time trends during 1995-2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000-07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern.

Findings: Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000-07. The overall incidence rose annually by 0.5% (99·8% CI 0·3-0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999-2001 to 2007-09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes.

Interpretation: Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.

Funding: The European Commission (Chafea).

Comment in

Similar articles

  • Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    AIRTUM Working Group, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomin A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L. AIRTUM Working Group, et al. Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748 Clinical Trial.
  • The European study on centralisation of childhood cancer treatment.
    Gatta G, Botta L, Comber H, Dimitrova N, Leinonen MK, Pritchard-Jones K, Siesling S, Trama A, Van Eycken L, van der Zwan JM, Visser O, Zagar T, Capocaccia R. Gatta G, et al. Eur J Cancer. 2019 Jul;115:120-127. doi: 10.1016/j.ejca.2019.04.024. Epub 2019 May 24. Eur J Cancer. 2019. PMID: 31132742 Clinical Trial.
  • Rare cancers are not so rare: the rare cancer burden in Europe.
    Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Gatta G, et al. Eur J Cancer. 2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25. Eur J Cancer. 2011. PMID: 22033323
  • The burden of rare cancers in Europe.
    Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. Gatta G, et al. Adv Exp Med Biol. 2010;686:285-303. doi: 10.1007/978-90-481-9485-8_17. Adv Exp Med Biol. 2010. PMID: 20824452 Review.
  • Improving treatment results with reference centres for rare cancers: where do we stand?
    Ray-Coquard I, Pujade Lauraine E, Le Cesne A, Pautier P, Vacher Lavenue MC, Trama A, Casali P, Coindre JM, Blay JY. Ray-Coquard I, et al. Eur J Cancer. 2017 May;77:90-98. doi: 10.1016/j.ejca.2017.02.006. Epub 2017 Apr 3. Eur J Cancer. 2017. PMID: 28384534 Review.
See all similar articles

Cited by 18 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback